Chronic Lyme Disease Treatments Tied to Serious Adverse Effects

Share this content:
Chronic Lyme Disease Treatments Tied to Serious Adverse Effects
Chronic Lyme Disease Treatments Tied to Serious Adverse Effects

MONDAY, June 19, 2017 (HealthDay News) -- Serious bacterial infections have been documented during treatment for chronic Lyme disease, according to research published in the June 16 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

Noting that chronic Lyme disease is used by some as a diagnosis for constitutional, musculoskeletal, and neuropsychiatric symptoms, Natalie S. Marzec, M.D., from the University of Colorado in Aurora, and colleagues address the issue of serious bacterial infections during treatments for chronic Lyme disease, detailing five illustrative cases.

The authors note that patients with a diagnosis of chronic Lyme disease are treated with a wide range of medications, including long courses of intravenous antibiotics. These treatments have not been shown to result in substantial long-term improvement, and they can be harmful. Cases of septic shock, osteomyelitis, Clostridium difficile colitis, and paraspinal abscess have been documented as a result of chronic Lyme disease treatments.

"Patients, clinicians, and public health practitioners should be aware that treatments for chronic Lyme disease can carry serious risks," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »